About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research conducted in our group is geared toward elucidating the cause and molecular mechanisms of neurodegeneration in Parkinson's disease (PD), a disabling, currently incurable common neurodegenerative disorder. To this end, we perform clinical and pre-clinical translational research in both PD patients and in human-relevant experimental in vitro and in vivo PD-related models.
Elucidating the molecular mechanisms underlying neurodegeneration in PD should allow to:
IP: Marta Martínez Vicente Collaborators: José Antonio Arranz Amo, Eddie Pradas Gracia, Laura Castillo Ribelles, Clara Carnicer Cáceres, David Moreno Martinez, New nanotechnological therapy for Parkinson's disease: nose-to-brain delivery of GBA-polymer nanoconjugates (NANOGBAtoBRAIN) Funding agency: Fundació "La Caixa" Funding: 249950 Reference: HR22-00602 Duration: 01/11/2022 - 31/10/2025
IP: Sara Marsal Barril Collaborators: Antonio Julia Cano, Javier Hoyo Pérez, DECISION ON OPTIMAL COMBINATORIAL THERAPIES IN IMIDS USING SYSTEMS APPROACHES (DOCTIS), DECISION ON OPTIMAL COMBINATORIAL THERAPIES IN IMIDS USING SYSTEMS APPROACHES (DOCTIS), Montse Sender Beleta, Nuria Palau Balaña, Edgar Nuñez Gallardo, Raul Tortosa Mendez, María Alba Erra Duran Funding agency: EUROPEAN COMMISSION Funding: 1079085 Reference: DOCTIS_H2020_SC1-BHC2019 Duration: 01/01/2020 - 31/12/2025
IP: Marta Martínez Vicente Collaborators: José Antonio Arranz Amo, Jorge Hernández Vara, Eddie Pradas Gracia, Guillem Pintos Morell, Clara Carnicer Cáceres, Carles Lorenzo Bosquet, David Moreno Martinez, Daniela Samaniego Toro, Laura Castillo Ribelles, The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies an Funding agency: Instituto de Salud Carlos III Funding: 245932.5 Reference: PI20/00728 Duration: 01/01/2021 - 30/06/2025
IP: Ariadna Laguna Tuset Collaborators: Maria Victoria Gonzalez Martinez, Miquel Vila Bover, Daniela Samaniego Toro, The brain-body axis in Parkinson’s disease patients: from pathophysiology to biomarkers and therapeutic approaches , Sara Belmonte Calderon Funding agency: Instituto de Salud Carlos III Funding: 171820 Reference: PI21/01603 Duration: 01/01/2022 - 30/06/2026
The event focused on advances in disease-modifying therapies and on the value of alliances between patients and professionals to promote more participatory care and research.
This VHIR initiative promotes well-being, empathy and community participation in Barcelona neighbourhoods through an intergenerational model
PAIR is an intergenerational initiative with people affected by Parkinson's disease and adolescents.
Vall d'Hebron Iniciativa per al Parkinson (VHIP) is a research project aimed at the development of biochemical markers for the early detection of Parkinson's disease. This study is carried out in people at high risk of having this disease, because they carry genetic mutations that predispose to the development of Parkinson's or because they present non-motor symptoms that manifest themselves years before motor symptoms.
